Skip to main navigation
Skip to main content
Prometheus Biosciences Logo Toggle Navigation Menu
  • Home
  • Our Story
    See Our Story Our Mission
  • Platform
  • Pipeline
    See Our Pipeline PRA023 PRA052
  • People
    Leadership Board of Directors Scientific Advisors
  • Careers
    Opportunities Benefits
  • Investors
    Overview News Releases Events & Presentations Financials Stock Analysts Governance IR Resources

Events & Presentations

Events & Presentations

Latest Corporate Presentation

Download PDF
Past Events

Oppenheimer 33rd Annual Healthcare Conference

Mar 13, 2023 at 10:40 AM EDT
Watch Webcast

PRA023 ARTEMIS-UC Presentation: 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

Mar 04, 2023
PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results 758.8 KB

PRA023 APPOLLO-CD Presentation: 18th Congress of European Crohn’s and Colitis Organisation (ECCO)

Mar 03, 2023
The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results 811.5 KB

SVB Securities Global Biopharma Conference

Feb 14, 2023 at 12:00 PM EST
Watch Webcast

Prometheus Biosciences ARTEMIS-UC and APOLLO-CD Phase 2 Announcement

Dec 07, 2022 at 8:30 AM EST
Watch Webcast
Prometheus Biosciences ARTEMIS-UC and APOLLO-CD Phase 2 Announcement Presentation 2 MB

R&D Day PR600 Target Unveiling

Jul 26, 2022 at 9:00 AM EDT
Watch Webcast
R&D Day PR600 Target Unveiling Presentation 6.3 MB

Prometheus Biosciences Phase 1 Data and New Indication Announcement Webcast

Dec 07, 2021 at 8:00 AM EST
Prometheus Biosciences Phase 1 Data and New Indication Announcement Presentation 4.1 MB
Subscribe to our Investor Alerts
Prometheus Biosciences Logo

Copyright © 2023 Prometheus Biosciences. All rights reserved

  • Contact Us
  • Terms & Conditions
  • Privacy Policy
  • Legal & Compliance
  • Notice of Privacy Practices
  • Accessibility Statement
  • Sitemap
LinkedIn Logo